Welcome to our dedicated page for Biodexa Pharmaceuticals plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biodexa Pharmaceuticals plc (NASDAQ: BDRX) SEC filings page on Stock Titan provides direct access to the company’s US regulatory disclosures as a foreign private issuer. Biodexa reports to the Securities and Exchange Commission primarily through Form 20-F for its annual report and Form 6-K for current reports on material developments. These filings document clinical, regulatory and financing milestones for its lead programs eRapa, tolimidone and MTX110.
Recent Form 6-K filings describe key events such as the approval of a Clinical Trial Application (CTA) by the European Medicines Agency for the pivotal Phase 3 Serenta trial of eRapa in familial adenomatous polyposis (FAP), enrollment of the first patients into that trial, and related press releases. Other 6-Ks outline corporate actions including ADR ratio changes, results of the company’s annual general meeting, and details of capital-raising transactions like equity line of credit arrangements and a best-efforts public offering of ADS Units and pre-funded units with accompanying Series L warrants.
Through these filings, investors can review information on offering structures, warrant terms, use of proceeds, grant funding supporting the eRapa FAP program, and updates on cash and cash equivalents at specified dates. The exhibits attached to 6-Ks often include full text of securities purchase agreements, placement agency agreements and warrant forms, providing additional detail on financing terms.
Stock Titan enhances access to BDRX filings with real-time updates from EDGAR and AI-powered summaries that explain the key points of lengthy documents such as current reports and registration-related materials. Users can quickly understand how new financings, clinical trial milestones or regulatory approvals described in Form 6-K may relate to Biodexa’s broader development strategy, while still having the option to read the full SEC documents for complete context.
Biodexa Pharmaceuticals has filed a prospectus supplement related to the potential resale of 341,352,000,000 ordinary shares (representing 34,135,200 American Depositary Shares). The company's ADSs trade on NASDAQ under symbol BDRX, with a last reported closing price of $0.9215 on June 26, 2025.
The filing also includes Form 6-K reporting the results of their Annual General Meeting held on June 26, 2025, where all proposed resolutions were passed. The company is advancing several key drug development programs:
- eRapa - An oral rapamycin formulation for Familial Adenomatous Polyposis and Non Muscle Invasive Bladder Cancer
- Tolimidone - A Lyn kinase inhibitor for type 1 diabetes treatment
- MTX110 - A panobinostat formulation for rare/orphan brain cancers
The company leverages three proprietary drug delivery technologies to improve bio-delivery and bio-distribution of medicines. Their R&D facility is located in Cardiff, UK.
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) filed a Form 6-K to report the outcome of its 26 June 2025 Annual General Meeting. The company confirms that every resolution listed in the 23 May 2025 AGM notice was duly approved by shareholders. Although the filing does not enumerate the resolutions or voting percentages, management notes that the results have been incorporated by reference into its effective registration statements on Form S-8 (No. 333-209365) and Form F-3 (No. 333-267932), thereby keeping those shelf offerings current.
A related press release dated 27 June 2025 (Exhibit 99.1) reiterates the successful passage of all motions. The press release is furnished—not filed—under the Exchange Act, limiting potential liability under Section 18.
No financial statements, earnings data, or strategic transaction details were included. The disclosure is largely procedural, aimed at satisfying SEC requirements and informing investors that corporate authorisations—potentially covering director re-elections, auditor appointment, remuneration, and share-issuance mandates—remain in force.